Galderma, a global leader in skin health focused on developing innovative aesthetic solutions, recently announced the Phase 2 clinical trial results for its novel ready-to-use investigational botulinum toxin, QM1114
| LAUSANNE, Switzerland, Oct. 9, 2019 /PRNewswire/ -- Galderma, a global leader in skin health focused on developing innovative aesthetic solutions, recently announced the Phase 2 clinical trial results for its novel ready-to-use investigational botulinum toxin, QM1114. The multicenter, randomized, double-blind, placebo-controlled study successfully demonstrated the safety and efficacy of Galderma’s liquid formulation of botulinum toxin type A for the treatment of glabellar lines (frown lines). The Phase 3 clinical trial program will begin soon to support regulatory submissions globally.1
“As a physician, I need to be confident that innovation in aesthetic treatment is the result of scientific rigor. I am encouraged by the results of the Phase 2 QM1114 study, which demonstrated initial safety and efficacy at all doses with high patient satisfaction,” said Dr. Joel Cohen*, Director of AboutSkin Dermatology and DermSurgery in Colorado, and investigator in the Phase 2 clinical trial. “It is exciting to see the development of a new toxin formulation that can offer convenience and the potential to eliminate the need for reconstitution in my practice.” Derived from Galderma’s proprietary strain of Clostridium botulinum bacteria and manufactured using an animal-origin free process, QM1114 has been designed and developed specifically for use in aesthetics. The QM1114 liquid formulation reduces preparation time needed in clinic and has the potential to increase accuracy, as it is ready-to-use, in contrast with current treatments that require reconstitution before administration. Market research suggests that on average, over 70 percent of injectors do not delegate the reconstitution process because they ‘do not feel comfortable with someone else doing it.’2 Additionally, Galderma recently received a manufacturing license from the Swedish Medical Products Agency (MPA) for a new state-of-the-art manufacturing facility at the Center of Excellence, located in Uppsala, Sweden.3 This new facility, built to the highest quality standards, is designed exclusively to meet the production and safety requirements of QM1114. It will also ensure that Galderma can meet increasing worldwide demand as the company’s innovative aesthetics pipeline grows. “Innovation is at the core of our business and our investment is backed by a trusted legacy of creating unique solutions that meet our customer needs,” said Alexandre Brennan, Global Head of Aesthetics, Galderma. “We are proud to be leaders in toxin research, and with these studies for a novel liquid formulation of botulinum toxin type A, we are building on our aesthetics heritage by advancing new treatments at our Center of Excellence in Sweden.” Pivotal Phase 3 trials for Galderma’s liquid formulation of botulinum toxin type A for the treatment of glabellar lines are expected to begin soon and enroll approximately 1,500 subjects. Galderma’s investment in the development of QM1114 is evidence of the company’s ongoing commitment to advancing the field of medical aesthetics through innovative solutions that create positive impact for aesthetics providers and their patients. About Galderma’s investigational drug, a liquid formulation of botulinum toxin type A for the treatment of glabellar lines About Galderma Contacts Isabella Laihorinne Smedh Victoria Smurro References
*Clinical Trial Investigator USMP/DYS/0222/0919(1) © 2019 Galderma Laboratories, L.P.
SOURCE Galderma |
View original content to download multimedia:
